Cytokinetics (CYTK) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Cytokinetics (CYTK) over the last 15 years, with Q3 2024 value amounting to $109.8 million.
- Cytokinetics' Total Current Liabilities rose 4128.64% to $109.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $109.8 million, marking a year-over-year increase of 4128.64%. This contributed to the annual value of $102.7 million for FY2023, which is 2134.44% up from last year.
- Cytokinetics' Total Current Liabilities amounted to $109.8 million in Q3 2024, which was up 4128.64% from $102.8 million recorded in Q2 2024.
- Cytokinetics' 5-year Total Current Liabilities high stood at $109.8 million for Q3 2024, and its period low was $20.7 million during Q1 2020.
- Over the past 5 years, Cytokinetics' median Total Current Liabilities value was $71.9 million (recorded in 2021), while the average stood at $66.8 million.
- As far as peak fluctuations go, Cytokinetics' Total Current Liabilities plummeted by 2106.79% in 2020, and later skyrocketed by 19328.69% in 2021.
- Quarter analysis of 5 years shows Cytokinetics' Total Current Liabilities stood at $31.2 million in 2020, then soared by 130.33% to $71.9 million in 2021, then rose by 17.75% to $84.6 million in 2022, then increased by 21.34% to $102.7 million in 2023, then grew by 6.95% to $109.8 million in 2024.
- Its last three reported values are $109.8 million in Q3 2024, $102.8 million for Q2 2024, and $88.9 million during Q1 2024.